Stock Events

Stock Events

Replimune Group 

$10.23
55
+$0.71+7.46% Friday 20:00
-$0.47-4.59%Friday 23:46After hours

Statistics

Day High
10.25
Day Low
10.23
52W High
13.24
52W Low
1.5
Volume
99,682
Avg. Volume
-
Mkt Cap
858.76M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.95
-0.84
-0.74
-0.63
Expected EPS
-0.627734
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-313.94MNet Income

Analyst Ratings

6.75Average Price Target
The highest estimate is 14.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
14%
Hold
57%
Sell
29%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow REPL. It's not an investment recommendation.
NVIDIA
14
NVDA
Tesla
12
TSLA
Alphabet
11
GOOGL
AMD
11
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap196.12B
Amgen Inc. has a broad portfolio in oncology, including immuno-oncology treatments that compete with Replimune's cancer therapies.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. offers Keytruda, a leading immunotherapy drug, which competes in the broader cancer treatment market against Replimune's products.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb has a strong lineup of cancer drugs, including immunotherapies that rival Replimune's approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, Inc. is involved in the development of cancer therapies, including cell therapies, which can be seen as competitive to Replimune's viral-based treatments.
Novavax
NVAX
Mkt Cap1.53B
Novavax, Inc., while primarily known for vaccines, is exploring cancer vaccine candidates that could potentially compete with Replimune's viral immunotherapies.
Iovance Biotherapeutics
IOVA
Mkt Cap1.89B
Iovance Biotherapeutics, Inc. specializes in tumor-infiltrating lymphocyte (TIL) therapies for cancer, offering a different but competitive approach to Replimune's methods.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. has a diverse oncology portfolio, including investments in immunotherapies that compete with the innovative cancer treatments developed by Replimune.

About

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Show more...
CEO
Dr. Sushil Patel Ph.D.
Employees
465
Country
United States
ISIN
US76029N1063

Listings

STU
DE
7R8.STU
MU
DE
7R8.MU
F
DE
7R8.F
XNAS
US
REPL

0 Comments

Share your thoughts

FAQ

What is Replimune Group stock price today?▼
The current price of REPL is $10.23 USD — it has increased by +7.46% in the past 24 hours. Watch Replimune Group stock price performance more closely on the chart.
What is Replimune Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Replimune Group stocks are traded under the ticker REPL.
Is Replimune Group stock price growing?▼
REPL stock has fallen by -6.92% compared to the previous week, the month change is a +0.39% rise, over the last year Replimune Group has showed a -15.38% decrease.
What is Replimune Group market cap?▼
Today Replimune Group has the market capitalization of 858.76M
When is the next Replimune Group earnings date?▼
Replimune Group is going to release the next earnings report on July 30, 2026.
What were Replimune Group earnings last quarter?▼
REPL earnings for the last quarter are -0.77 USD per share, whereas the estimation was -0.76 USD resulting in a -0.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Replimune Group revenue for the last year?▼
Replimune Group revenue for the last year amounts to 0 USD.
What is Replimune Group net income for the last year?▼
REPL net income for the last year is -313.94M USD.
How many employees does Replimune Group have?▼
As of July 18, 2026, the company has 465 employees.
In which sector is Replimune Group located?▼
Replimune Group operates in the Health & Wellness sector.
When did Replimune Group complete a stock split?▼
The last stock split for Replimune Group was on December 01, 2010 with a ratio of 15:1.
Where is Replimune Group headquartered?▼
Replimune Group is headquartered in Woburn, United States.